- Home
- RCEL vs GNLX Comparison
RCEL vs GNLX Comparison
Compare RCEL & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- GNLX
- Stock Information
- Founded
- RCEL N/A
- GNLX 2001
- Country
- RCEL United States
- GNLX United States
- Employees
- RCEL N/A
- GNLX N/A
- Industry
- RCEL Medical/Dental Instruments
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- RCEL Health Care
- GNLX Health Care
- Exchange
- RCEL Nasdaq
- GNLX Nasdaq
- Market Cap
- RCEL 140.5M
- GNLX 128.0M
- IPO Year
- RCEL N/A
- GNLX 2023
- Fundamental
- Price
- RCEL $5.54
- GNLX $4.45
- Analyst Decision
- RCEL Strong Buy
- GNLX Strong Buy
- Analyst Count
- RCEL 4
- GNLX 4
- Target Price
- RCEL $13.75
- GNLX $17.75
- AVG Volume (30 Days)
- RCEL 1.3M
- GNLX 146.1K
- Earning Date
- RCEL 11-06-2025
- GNLX 11-13-2025
- Dividend Yield
- RCEL N/A
- GNLX N/A
- EPS Growth
- RCEL N/A
- GNLX N/A
- EPS
- RCEL N/A
- GNLX N/A
- Revenue
- RCEL $74,884,000.00
- GNLX N/A
- Revenue This Year
- RCEL $22.92
- GNLX N/A
- Revenue Next Year
- RCEL $37.07
- GNLX N/A
- P/E Ratio
- RCEL N/A
- GNLX N/A
- Revenue Growth
- RCEL 38.32
- GNLX N/A
- 52 Week Low
- RCEL $3.60
- GNLX $1.99
- 52 Week High
- RCEL $14.16
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- RCEL 54.84
- GNLX 66.95
- Support Level
- RCEL $5.03
- GNLX $4.17
- Resistance Level
- RCEL $5.61
- GNLX $4.45
- Average True Range (ATR)
- RCEL 0.39
- GNLX 0.30
- MACD
- RCEL 0.00
- GNLX 0.02
- Stochastic Oscillator
- RCEL 34.69
- GNLX 80.65
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.